Advair Diskus Clinical Trials and Studies

Advair Diskus Information

Advair Diskus Clinical Trials and Studies

In clinical trials comparing Advair Diskus with the individual components, improvements in most efficacy endpoints were greater with Advair Diskus than with the use of either fluticasone propionate or salmeterol alone. In addition, clinical trials showed similar results between Advair Diskus and the concurrent use of fluticasone propionate plus salmeterol at corresponding doses from separate inhalers.

Studies Comparing Advair Diskus to Fluticasone Propionate Alone or Salmeterol Alone: Three double-blind, parallel-group clinical trials were conducted with Advair Diskus in 1,208 adolescent and adult patients (>12 years, baseline FEV1 63% to 72% of predicted normal) with asthma that was not optimally controlled on their current therapy. All treatments were inhalation powders, given as 1 inhalation from the Advair Diskus device twice daily, and other maintenance therapies were discontinued.

Study 1: Clinical Trial With Advair Diskus 100/50: This placebo-controlled, 12-week, US study compared Advair Diskus 100/50 with its individual components, fluticasone propionate 100 mcg and salmeterol 50 mcg. The study was stratified according to baseline asthma maintenance therapy; patients were using either inhaled corticosteroids (N = 250) (daily doses of beclomethasone dipropionate 252 to 420 mcg; flunisolide 1,000 mcg; fluticasone propionate inhalation aerosol 176 mcg; or triamcinolone acetonide 600 to 1,000 mcg) or salmeterol (N = 106). Baseline FEV1 measurements were similar across treatments: Advair Diskus 100/50, 2.17 L; fluticasone propionate 100 mcg, 2.11 L; salmeterol, 2.13 L; and placebo, 2.15 L.

Predefined withdrawal criteria for lack of efficacy, an indicator of worsening asthma, were utilized for this placebo-controlled study. Worsening asthma was defined as a clinically important decrease in FEV1 or peak expiratory flow (PEF), increase in use of Ventolin (albuterol, USP) Inhalation Aerosol, increase in night awakenings due to asthma, emergency intervention or hospitalization due to asthma, or requirement for asthma medication not allowed by the protocol. Statistically significantly fewer patients receiving Advair Diskus 100/50 were withdrawn due to worsening asthma compared with fluticasone propionate, salmeterol, and placebo.

Because this trial used predetermined criteria for worsening asthma, which caused more patients in the placebo group to be withdrawn, FEV1 results at Endpoint (last available FEV1 result) are also provided. Patients receiving Advair Diskus 100/50 had significantly greater improvements in FEV1 (0.51 L, 25%) compared with fluticasone propionate 100 mcg (0.28 L, 15%), salmeterol (0.11 L, 5%), and placebo (0.01 L, 1%). These improvements in FEV1 with Advair Diskus were achieved regardless of baseline asthma maintenance therapy (inhaled corticosteroids or salmeterol).

The subjective impact of asthma on patients' perception of health was evaluated through use of an instrument called the Asthma Quality of Life Questionnaire (AQLQ) (based on a 7-point scale where 1 = maximum impairment and 7 = none). Patients receiving Advair Diskus 100/50 had clinically meaningful improvements in overall asthma-specific quality of life as defined by a difference between groups of >0.5 points in change from baseline AQLQ scores (difference in AQLQ score of 1.25 compared to placebo).

Study 2: Clinical Trial With Advair Diskus 250/50: This placebo-controlled, 12-week, US study compared Advair Diskus 250/50 with its individual components, fluticasone propionate 250 mcg and salmeterol 50 mcg in 349 patients using inhaled corticosteroids (daily doses of beclomethasone dipropionate 462 to 672 mcg; flunisolide 1,250 to 2,000 mcg; fluticasone propionate inhalation aerosol 440 mcg; or triamcinolone acetonide 1,100 to 1,600 mcg). Baseline FEV1 measurements were similar across treatments: Advair Diskus 250/50, 2.23 L; fluticasone propionate 250 mcg, 2.12 L; salmeterol, 2.20 L; and placebo, 2.19 L.

Efficacy results in this study were similar to those observed in Study 1. Patients receiving

Advair Diskus 250/50 had significantly greater improvements in FEV1 (0.48 L, 23%) compared with fluticasone propionate 250 mcg (0.25 L, 13%), salmeterol (0.05 L, 4%), and placebo (decrease of 0.11 L, decrease of 5%). Statistically significantly fewer patients receiving Advair Diskus 250/50 were withdrawn from this study for worsening asthma (4%) compared with fluticasone propionate (22%), salmeterol (38%), and placebo (62%). In addition, Advair Diskus 250/50 was superior to fluticasone propionate, salmeterol, and placebo for improvements in morning and evening PEF. Patients receiving Advair Diskus 250/50 also had clinically meaningful improvements in overall asthma-specific quality of life as described in Study 1 (difference in AQLQ score of 1.29 compared to placebo).

Study 3: Clinical Trial With Advair Diskus 500/50: This 28-week, non-US study compared Advair Diskus 500/50 with fluticasone propionate 500 mcg alone and concurrent therapy (salmeterol 50 mcg plus fluticasone propionate 500 mcg administered from separate inhalers) twice daily in 503 patients using inhaled corticosteroids (daily doses of beclomethasone dipropionate 1,260 to 1,680 mcg; budesonide 1,500 to 2,000 mcg; flunisolide 1,500 to 2,000 mcg; or fluticasone propionate inhalation aerosol 660 to 880 mcg [750 to 1,000 mcg inhalation powder]). The primary efficacy parameter, morning PEF, was collected daily for the first 12 weeks of the study. The primary purpose of weeks 13 to 28 was to collect safety data.

Baseline PEF measurements were similar across treatments: Advair Diskus 500/50, 359 L/min; fluticasone propionate 500 mcg, 351 L/min; and concurrent therapy, 345 L/min. As shown in Figure 2, morning PEF improved significantly with Advair Diskus 500/50 compared with fluticasone propionate 500 mcg over the 12-week treatment period.

Improvements in morning PEF observed with Advair Diskus 500/50 were similar to improvements observed with concurrent therapy.

Advair Diskus Information